The world’s first clinical AI platform for the rapid prediction of severe respiratory disease has received CE-IVD accreditation, SIME Diagnostics has announced.
The CE-marked device is used by clinicians to routinely measure collected samples in 15 minutes via a reagent-free disposable. The device generates thousands of unique data points that are then analyzed by the platform’s proprietary algorithms to deliver results in life-critical situations.
The news report says that the company has also commenced work on a pilot of its RDS Predict application. The technology is used to identify which new-borns are most likely to develop respiratory distress syndrome.
By predicting the condition at birth, neonatologists can put in place early and preventative targeted treatment, improving outcomes and saving lives.
Pilot sites have been selected from the top neonatal intensive care units in Denmark, the UK and the US.
Join our Masterclass on ‘The New Reimbursement Pathway in France’ on 30th November. Click here to Request to Join.
Click here to read the original news article.